Highlights Bristol-Myers Squibb Company Borsa Italiana

Equities

4BMY

US1101221083

End-of-day quote Borsa Italiana Other stock markets 23:00:00 19/06/2024 BST			5-day change	1st Jan Change
37.96 ^EUR	-0.20%		-0.20%	-18.19%

06-26	2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	MT
06-26	Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	06-26	MT
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment	06-26	MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	06-26	MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	06-26	MT
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer	06-22	CI
US FDA approves Bristol Myers' colorectal cancer therapy	06-21	RE
Bristol Myers Squibb Announces European Medicines Agency Validates Extension Application to Introduce New Route of Administration (Subcutaneous Use) for Opdivo	06-21	CI
Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment	06-18	MT
Bristol Myers Squibb Keeps Quarterly Dividend at $0.60 a Share, Payable Aug. 1 to Shareholders of Record July 5	06-18	MT
Bristol Myers: Board declares dividend	06-18	CF
Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024	06-18	CI
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors	06-13	MT
Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors	06-13	CI
Evotec to Receive $20 Million Under Neuroscience Partnership with Bristol Myers Squibb	06-12	MT
Evotec Gets $20 Million Milestone Payment in Neurodegenerative Disease Collaboration With Bristol Myers Squibb	06-12	MT
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb	06-12	CI
ABL Bio, BMS Collaborate on Gastric Cancer Treatment Trial	06-10	MT
Geron shares surge after U.S. FDA approves blood disorder drug	06-07	RE
I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	06-05	MT
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	06-05	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 06:06 pm